Faron Pharmaceuticals Oy

Notice of Half-Year Report

Thu, Aug 27, 2020 08:00 CET

Faron Pharmaceuticals Ltd (“Faron” or the “Company”)Company announcement, 27 August 2020 at 9.00 AM (EET) TURKU – FINLAND, 27 August 2020 – Faron Pharmaceuticals Ltd (“Faron”) (LON: FARN), the clinical stage biopharmaceutical company, will announce its unaudited half-year report for the six months ended 30 June 2020 on Thursday 24 September 2020. Dr. Markku Jalkanen, Chief Executive Officer, Toni Hänninen, Chief Financial Officer, and Yrjö Wichmann, VP Financing will host a conference call and webcast followed by a Q&A session at 12:30 pm BST (7:30 am EST) to discuss the financial

Managers’ transactions

Wed, Jul 08, 2020 16:00 CET

(“Faron” or the “Company”)Company announcement, 8 July 2020 at 5 PM (EEST) TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces today that Mr Toni Hänninen, Chief Financial Officer of the Company, acquired 4,400 ordinary shares in Faron at a price of €3.510 per share on 8 July 2020. Following these purchases, Mr Hänninen holds 54,697 ordinary shares in the Company. The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Share

Notice of Half-Year Report

Managers’ transactions

Subscribe